Qube Research & Technologies LTD Altimmune, Inc. Transaction History

Qube Research & Technologies LTD

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$2.4 - $3.45 $1.76 Million - $2.52 Million	-731,542 Reduced 80.37%	178,697 $464,000
Q2 2023 Aug 14, 2023	BUY	$3.45 - $5.97 $785,078 - $1.36 Million	227,559 Added 33.33%	910,239 $3.21 Million
Q1 2023 May 15, 2023	BUY	$4.19 - $16.83 $2.81 Million - $11.3 Million	670,035 Added 5298.81%	682,680 $2.88 Million
Q4 2022 Feb 14, 2023	SELL	$8.74 - $16.45 $191,703 - $360,814	-21,934 Reduced 63.43%	12,645 $208,000
Q3 2022 Nov 14, 2022	BUY	$10.67 - $22.41 $368,957 - $774,915	34,579 New	34,579 $442,000
Q2 2021 Aug 13, 2021	SELL	$9.85 - $16.46 $173,803 - $290,436	-17,645 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$12.71 - $24.31 $720,822 - $1.38 Million	-56,713 Reduced 76.27%	17,645 $249,000
Q4 2020 Feb 16, 2021	BUY	$7.84 - $14.22 $466,236 - $845,649	59,469 Added 399.42%	74,358 $839,000
Q3 2020 Nov 12, 2020	BUY	$9.93 - $33.26 $147,847 - $495,208	14,889 New	14,889 $197,000

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $404M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.